Rhumbline Advisers Acquires 33,117 Shares of Nkarta, Inc. (NASDAQ:NKTX)

Rhumbline Advisers boosted its holdings in shares of Nkarta, Inc. (NASDAQ:NKTX) by 65.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 84,011 shares of the company’s stock after purchasing an additional 33,117 shares during the period. Rhumbline Advisers owned about 0.17% of Nkarta worth $496,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of NKTX. GAMMA Investing LLC lifted its holdings in shares of Nkarta by 1,887.0% in the 2nd quarter. GAMMA Investing LLC now owns 4,729 shares of the company’s stock worth $28,000 after buying an additional 4,491 shares during the period. Sierra Summit Advisors LLC bought a new stake in shares of Nkarta in the fourth quarter valued at about $78,000. Vanguard Personalized Indexing Management LLC lifted its stake in Nkarta by 22.5% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 14,226 shares of the company’s stock worth $94,000 after acquiring an additional 2,613 shares during the period. Catalina Capital Group LLC bought a new position in Nkarta during the 1st quarter worth about $146,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Nkarta during the 1st quarter valued at about $146,000. Institutional investors own 80.54% of the company’s stock.

Insider Buying and Selling

In other Nkarta news, insider Alicia J. Hager sold 3,396 shares of the stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $8.00, for a total value of $27,168.00. Following the completion of the sale, the insider now directly owns 103,819 shares in the company, valued at $830,552. The transaction was disclosed in a document filed with the SEC, which is available at this link. 8.70% of the stock is owned by company insiders.

Nkarta Stock Down 1.1 %

NASDAQ NKTX opened at $4.70 on Thursday. Nkarta, Inc. has a 52 week low of $1.28 and a 52 week high of $16.24. The company has a 50 day moving average price of $5.69 and a 200 day moving average price of $6.96. The firm has a market cap of $331.63 million, a PE ratio of -2.02 and a beta of 0.81.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.15. On average, equities research analysts anticipate that Nkarta, Inc. will post -1.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on NKTX. HC Wainwright lowered their price target on shares of Nkarta from $23.00 to $22.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. Raymond James upgraded Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 target price for the company in a report on Wednesday, August 14th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $13.00 price target on shares of Nkarta in a report on Wednesday, August 14th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Nkarta has an average rating of “Buy” and an average price target of $18.20.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.